More than 95% of patients with RTT carry loss of function mutations in the X-linked Methyl-CpG-binding Protein 2 (MECP2) gene [9,10], encoding a key epigenetic modulator of transcription crucial for maturation of neurons and for nervous system functioning [11]. Here, MECP2 is linked to Rett syndrome.